Literature DB >> 7128000

Significance of lipoproteins in serum binding variations of amitriptyline, nortriptyline, and quinidine.

E Pike, B Skuterud, P Kierulf, P K Lunde.   

Abstract

Using isotope technique, the serum binding of amitriptyline (AT), nortriptyline (NT), and quinidine (Q) was measured by equilibrium dialysis in sera containing varying amounts of lipoproteins. Sera were obtained from 10 fasting subjects with normal to grossly elevated levels of cholesterol, triglycerides, or both. When the lipoproteins were removed from eight of the sera by a standard ultracentrifugation technique, the ratio bound/unbound (B/F) AT decreased an average of 47% (range 30% to 68%), NT an average of 54% (range 39% to 67%), and Q an average of 6% (range 0 to 16%). This decrease in the ratio B/F correlated linearly with the sum of serum concentrations of cholesterol and triglycerides for AT (r = 0.88) and NT (r = 0.82), but not for Q (r = 0.15). In three lipoprotein-depleted sera resuspended with lipoproteins at eight different concentrations ranging from 0 to 100% of the original content, there was a linear correlation between the ratio B/F for AT and NT and the lipoproteins, as evidence by cholesterol or triglycerides concentrations (r = 0.97 to 0.99), but not for Q (r = -0.17 to 0.36). Finally, in the original 10 serum samples, there was a linear correlation between the ratio B/F and the serum lipoproteins (sum of cholesterol and triglycerides) for AT (r = 0.89) and NT (r = 0.68), whereas there was no such relationship for Q (r = -0.15). These data indicate that basic drugs differ in binding characteristics (probably depending on lipophility).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7128000     DOI: 10.1038/clpt.1982.209

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline.

Authors:  A G Teschemacher; E P Seward; J C Hancox; H J Witchel
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

Review 2.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

3.  Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin.

Authors:  N Simon; E Dailly; O Combes; E Malaurie; M Lemaire; J P Tillement; S Urien
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

4.  Pharmacokinetics of quinidine in male patients. A population analysis.

Authors:  C N Verme; T M Ludden; W A Clementi; S C Harris
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

5.  Interaction of mixed micelles formed from glycocholic acid and lecithin with the protein binding of various drugs.

Authors:  T W Guentert; S Oie; L Paalzow; B M Frey; R Brandt; L J Aarons; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335

6.  Interindividual differences in the binding of antidepressives to plasma proteins: the role of the variants of alpha 1-acid glycoprotein.

Authors:  D Tinguely; P Baumann; M Conti; M Jonzier-Perey; J Schöpf
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 7.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

8.  Rat and rabbit plasma distribution of free and chylomicron-associated BIRT 377, a novel small molecule antagonist of LFA-1-mediated cell adhesion.

Authors:  K M Wasan; M Ramaswamy; L Holtorf; A A Jayaraj; D J Hauss
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

9.  Lack of accumulation of midazolam in plasma and lipoprotein fractions during intravenous lipid infusions in patients on artificial respiration.

Authors:  I Walter-Sack; J X de Vries; J Rudi; R Conradi; M Kohlmeier; B Kohl; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

10.  Drug binding in sera deficient in lipoproteins, albumin or orosomucoid.

Authors:  E Pike; P Kierulf; B Skuterud; J E Bredesen; P K Lunde
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.